Brought to you by 
Sobi gets rights to Valeant's urea cycle disorder drug Ammonul
22 Feb 2017
Executive Summary
In a three-year deal, Valeant Pharmaceuticals International Inc. licensed Swedish Orphan Biovitrum AB (Sobi) exclusive rights to sell and distribute Ammonul (sodium phenyl acetate and sodium benzoate) injection in Europe, the Middle East, and North Africa.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sobi gets rights to Valeant's urea cycle disorder drug Ammonul
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice